Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, filed a Form 4 on November 18, 2026, disclosing the sale of 100,000 Class A Ordinary Shares on November 17, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Sale transaction: Hite disposed of 100,000 Class A Ordinary Shares on November 17, 2026, at a weighted average price of $68.1471 per share.
  • Price range: The shares were sold in multiple transactions at prices ranging from $67.78 to $68.58 per share, according to the filing.
  • 10b5-1 plan: The transactions were effected pursuant to a Rule 10b5-1 plan adopted by Hite on March 20, 2026.
  • Remaining indirect holdings: Following the transaction, 177,523 Class A Ordinary Shares are held indirectly by SCH Investment Partners LLC, and 23,200 Class A Ordinary Shares are held directly.
  • Additional interests: Family vehicles controlled by Hite hold limited partnership interests exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Hite's November 2026 Share Sale at Royalty Pharma

According to the Form 4 filed with the SEC on November 18, 2026, Christopher Hite, identified as EVP and Chairman of Partnering at Royalty Pharma plc (NASDAQ:RPRX), reported the disposal of 100,000 Class A Ordinary Shares. The transaction was coded "S" and carried a weighted average sale price of $68.1471 per share. The filing notes that the shares were sold in multiple transactions at prices ranging from $67.78 to $68.58 per share, and that Hite undertakes to provide full information on the number of shares sold at each separate price within that range upon written request.

The filing states that all reported transactions were effected pursuant to a 10b5-1 plan adopted by Hite on March 20, 2026. Following the reported transaction, the filing discloses that 177,523 Class A Ordinary Shares remain held indirectly through SCH Investment Partners LLC, and 23,200 Class A Ordinary Shares are held directly by the reporting person.

In a separate remark, the filing discloses that family vehicles controlled by Hite hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares, as well as Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, with the Class E Ordinary Shares noted as "subject to vesting conditions." The Form 4 was signed by Sean Weisberg as Attorney-in-Fact for Christopher Hite.

What Was Disclosed

Royalty Pharma plc officer Christopher Hite filed a Form 4 reporting the sale of 100,000 Class A Ordinary Shares on November 17, 2026, at a weighted average price of $68.1471, under a pre-established 10b5-1 trading plan adopted March 20, 2026.